Reduced Krüppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy

Kidney International

Volumn 87, Issue 2, 2015, Pages 382-395

  Zhong, Fang ^a,b   Chen, Habing ^a,c   Wei, Chengguo ^a   Zhang, Weijia ^a   Li, Zhengzhe ^a   Jain, Mukesh K ^d   Chuang, Peter Y ^a   Chen, Hongyu ^b   Wang, Yongjun ^b   Mallipattu, Sandeep K ^e   He, John C ^a,f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

diabetic nephropathy; endothelium; podocyte

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; KRUPPEL LIKE FACTOR 2; PROTEIN ZO1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; INSULIN; KLF2 PROTEIN, MOUSE; KLF2 PROTEIN, RAT; KRUPPEL LIKE FACTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN CELL; KIDNEY HYPERTROPHY; MALE; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEINURIA; RAT; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DIABETIC NEPHROPATHIES; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GLOMERULUS; INJURIES; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INSULIN; KIDNEY GLOMERULUS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, KNOCKOUT; PODOCYTES; RATS; RNA, MESSENGER;

EID: 84922133339     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.286     Document Type: Article

References (56)

1. Collins AJ, Foley RN, Chavers B et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 2014; 63: A7.
2. Premaratne E, Macisaac RJ, Tsalamandris C et al. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia 2005; 48: 2486-2493.
3. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
4. Dei Cas A, Gnudi L. VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Metabolism 2012; 61: 1666-1673.
5. Yuen DA, Stead BE, Zhang YL et al. eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol 2012; 23: 1810-1823.
6. Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669.
7. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007; 292: F1665-F1672.
8. Isermann B, Vinnikov IA, Madhusudhan T et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13: 1349-1358.
9. Haraldsson B, Nystrom J. The glomerular endothelium: new insights on function and structure. Curr Opin Nephrol Hypertens 2012; 21: 258-263.
10. Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Pathol 2012; 226: 562-574.
11. Daehn I, Casalena G, Zhang T et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014; 124: 1608-1621.
12. Feinberg MW, Lin Z, Fisch S et al. An emerging role for Kruppel-like factors in vascular biology. Trends Cardiovasc Med 2004; 14: 241-246.
13. Pearson R, Fleetwood J, Eaton S et al. Kruppel-like transcription factors: a functional family. Int J Biochem Cell Biol 2008; 40: 1996-2001.
14. Kuo CT, Veselits ML, Leiden JM. LKLF: a transcriptional regulator of singlepositive T cell quiescence and survival. Science 1997; 277: 1986-1990.
15. Carlson CM, Endrizzi BT, Wu J et al. Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature 2006; 442: 299-302.
16. Das H, Kumar A, Lin Z et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci USA 2006; 103: 6653-6658.
17. Weinreich MA, Takada K, Skon C et al. KLF2 transcription-factor deficiency in T cells results in unrestrained cytokine production and upregulation of bystander chemokine receptors. Immunity 2009; 31: 122-130.
18. Lee JS, Yu Q, Shin JT et al. Klf2 is an essential regulator of vascular hemodynamic forces in vivo. Dev Cell 2006; 11: 845-857.
19. Parmar KM, Larman HB, Dai G et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. J Clin Invest 2006; 116: 49-58.
20. Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circ Res 2007; 100: 1686-1695.
21. Lin ZY, Natesan V, Shi H et al. Kruppel-like factor 2 regulates endothelial barrier function. Arterioscler Thromb Vasc Biol 2010; 30: 1952-U1181.
22. Chiplunkar AR, Curtis BC, Eades GL et al. The Kruppel-like factor 2 and Kruppel-like factor 4 genes interact to maintain endothelial integrity in mouse embryonic vasculogenesis. BMC Dev Biol 2013; 13: 40.
23. Bhattacharya R, Senbanerjee S, Lin Z et al. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem 2005; 280: 28848-28851.
24. Lin Z, Kumar A, SenBanerjee S et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 2005; 96: e48-e57.
25. SenBanerjee S, Lin Z, Atkins GB et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004; 199: 1305-1315.
26. Agustian PA, Bockmeyer CL, Modde F et al. Glomerular mRNA expression of prothrombotic and antithrombotic factors in renal transplants with thrombotic microangiopathy. Transplantation 2013; 95: 1242-1248.
27. Slater SC, Ramnath RD, Uttridge K et al. Chronic exposure to laminar shear stress induces Kruppel-like factor 2 in glomerular endothelial cells and modulates interactions with co-cultured podocytes. Int J Biochem Cell Biol 2012; 44: 1482-1490.
28. Lee HY, Youn SW, Oh BH et al. Kruppel-like factor 2 suppression by high glucose as a possible mechanism of diabetic vasculopathy. Korean Circ J 2012; 42: 239-245.
29. Azeloglu EU, Hardy SV, Eungdamrong NJ et al. Interconnected network motifs control podocyte morphology and kidney function. Sci Signal 2014; 7: ra12.
30. Hodgin JB, Nair V, Zhang H et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013; 62: 299-308.
31. Mallipattu SK, Liu R, Zheng F et al. Kruppel-like factor 15 (KLF15) is a key regulator of podocyte differentiation. J Biol Chem 2012; 287: 19122-19135.
32. Dekker RJ, Boon RA, Rondaij MG et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 2006; 107: 4354-4363.
33. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51: 714-725.
34. Wingender E, Chen X, Hehl R et al. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 2000; 28: 316-319.
35. Wasserman WW, Sandelin A. Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 2004; 5: 276-287.
36. Cartharius K, Frech K, Grote K et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933-2942.
37. Dellamea BS, Leitao CB, Friedman R et al. Nitric oxide system and diabetic nephropathy. Diabetol Metab Syndr 2014; 6: 17.
38. Cheng H, Wang H, Fan X et al. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/ db mice. Kidney Int. 2012; 82: 1176-1183.
39. Sivaskandarajah GA, Jeansson M, Maezawa Y et al. Vegfa protects the glomerular microvasculature in diabetes. Diabetes 2012; 61: 2958-2966.
40. Young A, Wu W, Sun W et al. Flow activation of AMP-Activated protein kinase in vascular endothelium leads to Kruppel-like factor 2 expression. Arterioscler Thromb Vasc Biol 2009; 29: 1902-1908.
41. Fledderus JO, Boon RA, Volger OL et al. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 1339-1346.
42. Kumar A, Hoffman TA, Dericco J et al. Transcriptional repression of Kruppel like factor-2 by the adaptor protein p66shc. FASEB J 2009; 23: 4344-4352.
43. Bock F, Shahzad K, Wang H et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA 2013; 110: 648-653.
44. Zahlten J, Steinicke R, Opitz B et al. TLR2-And nucleotide-binding oligomerization domain 2-dependent Kruppel-like factor 2 expression downregulates NF-kappa B-related gene expression. J Immunol 2010; 185: 597-604.
45. Nayak L, Goduni L, Takami Y et al. Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol 2013; 182: 1696-1704.
46. Lin Z, Hamik A, Jain R et al. Kruppel-like factor 2 inhibits protease activated receptor-1 expression and thrombin-mediated endothelial activation. Arterioscler Thromb Vasc Biol 2006; 26: 1185-1189.
47. Sakai T, Nambu T, Katoh M et al. Up-regulation of protease-Activated receptor-1 in diabetic glomerulosclerosis. Biochem Biophys Res Commun 2009; 384: 173-179.
48. London NR, Whitehead KJ, Li DY. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 2009; 12: 149-158.
49. Macconi D, Ghilardi M, Bonassi ME et al. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol 2000; 11: 477-489.
50. Wani MA, Means RT Jr, Lingrel JB. Loss of LKLF function results in embryonic lethality in mice. Transgenic Res 1998; 7: 229-238.
51. Gassmann M, Grenacher B, Rohde B et al. Quantifying Western blots: pitfalls of densitometry. Electrophoresis 2009; 30: 1845-1855.
52. Kume S, Uzu T, Araki S et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 2007; 18: 2715-2723.
53. Koop K, Eikmans M, Baelde HJ et al. Expression of podocyte-Associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14: 2063-2071.
54. Takemoto M, Asker N, Gerhardt H et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002; 161: 799-805.
55. Sobczak M, Dargatz J, Chrzanowska-Wodnicka M. Isolation and culture of pulmonary endothelial cells from neonatal mice. J Vis Exp 2010; 46: 2316.
56. Potapova TA, Sivakumar S, Flynn JN et al. Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited. Mol Biol Cell 2011; 22: 1191-1206.